30 results
Primary objective: * Examine the safety and tolerability, both local and general, of ProCervix Solution (escalating doses) and ProCervix Powder in women infected by HPV 16 and/or 18 with normal cytology from Week 0 to Week 10. Secondary objectives…
To evaluate patient related outcomes mainly quality of life and treatment satisfaction. Side effects and therapy adherence were also evaluated because these can interfere with quality of life and treatment satisfaction.
Primary ObjectiveTo explore the pharmacodynamics effects of topically applied OMN ono Tape-stripped skin of healthy volunteerso Tape-stripped and IMQ-primed skin of healthy volunteerso Tape-stripped skin prior to IMQ applicationSecondary Objectives…
Primary objective- To explore the pharmacodynamic effects of topically applied IMQ (in combination with or without TS) - To identify dose-response relationship of topically applied IMQ Secondary objective- To assess safety and tolerability of…
To assess the safety, tolerability, biomarker and cognitive efficacy of investigational products in subjects who are known to have an Alzheimer*s disease-causing mutation by determining if treatment with the study drug slows the rate of progression…
Primary objective: To compare long-term efficacy of curettage prior to IMQ 5% cream (Aldara®) therapy versus standard surgical excision in primary nBCC.Secondary objective: To assess compliance, pain, cosmetic outcomes, patient satisfaction, patient…
Primary Objective:- Number of participants with dose limiting toxicity - Number of participants with treatment-related adverse events - Number of participants with treatment-emergent adverse events- Number of participants with changes in vital signs…
Primary study aim:To determine the efficacy, in terms of the meadian progression-free survival, in patients with recurrent or metastatic endometrial cancer (including carcinosarcoma of the endometrium) receiving treatment with durvalumab and…
Primary objectives: 1. To assess the effect of experimental immunization with GA2 sporozoites by mosquito bite with and without co-administration of different adjuvants on the pre-patent period after controlled human malaria infection (CHMI).2. To…
This study will evaluate the efficacy and safety of consolidation maintenance treatment consisting of atezolizumab and tiragolumab compared with durvalumab in patients with locally advanced, unresectable Stage III NSCLC who have received at least…
(1) Main objective:Safety Run-In (SRI):To assess the safety and tolerability of durvalumab + tremelimumab + EV in participants with MIBC who are ineligible for cisplatin or who refuse cisplatinMain Study: To compare the efficacy of durvalumab +…
The research hypothesis for this study is that concurrent durvalumab plus SoC chemotherapy will be more effective than placebo plus SoC chemotherapy for the treatment of MRD+ patients who have undergone complete resection of stage II-III NSCLC when…
Primary:• 3 year recurrence free survival (RFS), in patients with MMRd HREC Secondary:• RFS (median and at 5 years)• OS (median, 3yr, 5yr)• Vaginal RFS, pelvic RFS, distant metastasis free-survival (median, 3-year, 5-year)• Disease-specific…
- To assess the safety and tolerability and to determine the RP2D of T-DXd plus durvalumab in combination with cisplatin, carboplatin or pemetrexed
This study is evaluating the preliminary efficacy of UV1-olaparib-durvalumab combination against both olaparib as monotherapy and olaparib-durvalumab combination in maintenance after platinum combination therapy for BRCAwt patients with relapsed…
The overall objectives of this study are to evaluate the efficacy and safety of multiple therapies in patients with locally advanced, unresectable, Stage III NSCLC who are selected according to biomarker status as identified by tissue-based testing.…
The standard first-line therapy for mUC patients is platinum-based chemotherapy, most commonly cisplatin. For patients that progress during or after platinum-based chemotherapy, anti-PD(L)1 therapy can be used, showing durable responses in a subset…
To evaluate PFS in participants treated with cCRT plus M7824 followed by M7824 or cCRT plus placebo followed by Durvalumab
Primary* To immunologically characterize imiquimod-induced inflammation after 7-day exposure of healthy skin;* To evaluate local complement activation/depositions after a prolonged topical imiquimod challenge;* To evaluate systemic activation of…
In this study, we want to learn more about the effect and safety of Ceralasertib plus Durvalumab on the inhibition of tumour growth, and also to better understand NSCLC and associated health problems.We compare the effect and safety of Ceralasertib…